Abstract
The call for the discovery of less toxic, more selective, and more effective agents to treat cancer has become more urgent. Inhibition of angiogenesis continues to be one of the main streams in the current cancer drug discovery activity. Insights into tumor angiogenesis biology have led to the identification of a number of molecules, which are important for the progression of these processes. Of particular interest is a group of growth factors including fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor. These growth factors and their corresponding receptor tyrosine kinases have become important targets for inhibition of the proliferation of endothelial cells, the main component of blood vessels. The validated targets for inhibition of angiogenesis also include a family of matrix metalloproteinases and cell adhesion molecules. In the closely related area, protein kinases have emerged as one of the most important targets for drug discovery. Besides growth factor receptor tyrosine kinases, numerous other protein kinases implicated in malignancies have been identified including non-receptor kinases such as Bcl-Abl and Src kinases. In addition, the cell cycle regulators (cyclin-dependent kinases, p21 gene) and apoptosis modulators (Bcl-2 oncoprotein, p53 tumor suppressor gene, survivin protein, etc) have also attracted renewed interest as potential targets for anticancer drug discovery. Other molecular targets include protein farnesyltransferase (FTase), histone deacetylase (HDAC), and telomerase, which have essential roles in cellular signal transduction pathways (FTase, HDAC) and cell life-span (telomerase). This review presents a comprehensive summary and discussion on the most important targets currently attracting a great deal of interest in contemporary anticancer drug design and discovery. Recent advances complementing these targets are also highlighted.
Keywords: anticancer drugs, anticancer targets, anticancer drug discovery
Current Drug Targets
Title: Current Targets for Anticancer Drug Discovery
Volume: 4 Issue: 2
Author(s): Nguyen-Hai Nam and Keykavous Parang
Affiliation:
Keywords: anticancer drugs, anticancer targets, anticancer drug discovery
Abstract: The call for the discovery of less toxic, more selective, and more effective agents to treat cancer has become more urgent. Inhibition of angiogenesis continues to be one of the main streams in the current cancer drug discovery activity. Insights into tumor angiogenesis biology have led to the identification of a number of molecules, which are important for the progression of these processes. Of particular interest is a group of growth factors including fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor. These growth factors and their corresponding receptor tyrosine kinases have become important targets for inhibition of the proliferation of endothelial cells, the main component of blood vessels. The validated targets for inhibition of angiogenesis also include a family of matrix metalloproteinases and cell adhesion molecules. In the closely related area, protein kinases have emerged as one of the most important targets for drug discovery. Besides growth factor receptor tyrosine kinases, numerous other protein kinases implicated in malignancies have been identified including non-receptor kinases such as Bcl-Abl and Src kinases. In addition, the cell cycle regulators (cyclin-dependent kinases, p21 gene) and apoptosis modulators (Bcl-2 oncoprotein, p53 tumor suppressor gene, survivin protein, etc) have also attracted renewed interest as potential targets for anticancer drug discovery. Other molecular targets include protein farnesyltransferase (FTase), histone deacetylase (HDAC), and telomerase, which have essential roles in cellular signal transduction pathways (FTase, HDAC) and cell life-span (telomerase). This review presents a comprehensive summary and discussion on the most important targets currently attracting a great deal of interest in contemporary anticancer drug design and discovery. Recent advances complementing these targets are also highlighted.
Export Options
About this article
Cite this article as:
Nam Nguyen-Hai and Parang Keykavous, Current Targets for Anticancer Drug Discovery, Current Drug Targets 2003; 4 (2) . https://dx.doi.org/10.2174/1389450033346966
DOI https://dx.doi.org/10.2174/1389450033346966 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Escape from Immune Response: Mechanisms and Targets of Activity
Current Drug Targets MMPs in Ovarian Cancer as Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry A Fluorescent Alkyllysophospholipid Analog Exhibits Selective Cytotoxicity Against the Hormone-Insensitive Prostate Cancer Cell Line PC3
Anti-Cancer Agents in Medicinal Chemistry Application of Molecular Imaging Technologies in Antitumor Drug Development and Therapy
Current Pharmaceutical Design Anti-Angiogenesis in Glioblastoma: The Clinical Consequences of Redundancy and Evasion?
Current Angiogenesis (Discontinued) Drugs for AIDS
Mini-Reviews in Medicinal Chemistry Akt Pathway Inhibitors
Current Topics in Medicinal Chemistry Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies
Current Topics in Medicinal Chemistry p38 MAP Kinase Interacts with and Stabilizes Pancreatic and Duodenal Homeobox-1
Current Molecular Medicine MicroRNA-7 Regulates Insulin Signaling Pathway by Targeting IRS1, IRS2, and RAF1 Genes in Gestational Diabetes Mellitus
MicroRNA miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy Feasibility of Targeting Glioblastoma Stem Cells: From Concept to Clinical Trials
Current Topics in Medicinal Chemistry A Mini Review on Interactions Between Neural Stem Cells and Biomaterials
Recent Patents on Regenerative Medicine Progress on Multi-Modality Molecular Imaging
Current Medical Imaging Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Age and Dose-Dependent Effects of Alpha-Lipoic Acid on Human Microtubule- Associated Protein Tau-Induced Endoplasmic Reticulum Unfolded Protein Response: Implications for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Technological Maturity and Systematic Review of Medicinal Plants with Pharmacological Activity in the Central Nervous System
Recent Patents on Biotechnology State-of-the-Art Methodologies for the Discovery and Characterization of DNA G-Quadruplex Binders
Current Pharmaceutical Design Dendritoma Vaccine for Cancer: A Hopeful Approach
Current Cancer Therapy Reviews A Novel Marine Drug, SZ–685C, Induces Apoptosis of MMQ Pituitary Tumor Cells by Downregulating miR–200c
Current Medicinal Chemistry